openPR Logo
Press release

Urothelial Carcinoma Treatment Market Therapeutics Survey Report by GlaxoSmithKline plc, Genentech, Inc., Novartis AG, Dendreon, Merck KGaA, Eisai Co., Sanofi S.A., Bristol-Myers Squibb | MRFR Briefing 2018

12-11-2018 08:19 PM CET | Advertising, Media Consulting, Marketing Research

Press release from: Market Research Future

Urothelial Carcinoma Treatment Market Therapeutics Survey

Urothelial carcinoma is also called as transitional cell carcinoma which is a cancerous tumor of the bladder that can spread to other parts of the body. These are also called as malignant tumors. This tumor can start at any part of the urinary tract. People with bladder cancer may also have similar cancer in other parts of the urinary tract.

Global urothelial carcinoma treatment market is expected to grow over the forecast period of 2023 and is expected to register a CAGR ~7.8% during the forecast period of 2018–2023.

Hence the urothelial carcinoma treatment market is expected to grow due to increasing prevalence of bladder cancer. Increasing investment in R&D activities to come up with new cancer treatment is also boosting the market for urothelial carcinoma treatment. As various awareness programs are carried out by government and non-government organizations regarding bladder cancer, it is expected to boost the urothelial carcinoma treatment market during the forecast period.

Key players

Key players for the global urothelial carcinoma treatment market are GlaxoSmithKline plc, Genentech, Inc., Novartis AG, Dendreon, Merck KGaA, Eisai Co., Sanofi S.A., Bristol-Myers Squibb.

Avail Sample Copy for this Report at https://www.marketresearchfuture.com/sample_request/6444

Segmentation

The global urothelial carcinoma treatment market has been segmented on the basis of types, treatment, and end-users. Based on type the global urothelial carcinoma treatment is segmented into non-invasive and invasive urothelial carcinoma treatment. On basis of treatment, the market is segmented into immunotherapy, radiotherapy, and chemotherapy. Based on end-user the urothelial carcinoma market is segmented into hospital pharmacy, retail pharmacy, and others.

Intended Audience

Hospitals and clinics
Laboratories and associations
The Middle East and Africa has the lowest market for urothelial carcinoma treatment due to poor medical facilities and lack of technology.

Global Urothelial Carcinoma Treatment Market, by Type

Non-invasive urothelial carcinoma treatment
Invasive urothelial carcinoma treatment
Global Urothelial Carcinoma Treatment Market, by Treatment

Immunotherapy
Radiotherapy
Chemotherapy
Global Urothelial Carcinoma Treatment Market, by End-User

Hospital pharmacy
Retail pharmacy
Others
Browse Complete Research Report Enabled with Respective Tables and Figures at https://www.marketresearchfuture.com/reports/urothelial-carcinoma-treatment-market-6444

Regional Analysis

On a regional basis, the market is segmented into Americas, Europe, Asia-Pacific, Middle East, and Africa.

Americas is likely to dominate the urothelial carcinoma treatment market owing to the increasing prevalence of bladder cancer, increasing investment in research and development of new bladder cancer treatment. According to the American cancer society report, about 79030 cases of bladder cancer was reported in 2017 in the US.

Europe is the second largest market for the urothelial carcinoma treatment followed by Asia-Pacific. Due to growing awareness regarding early diagnosis of bladder cancer and developed healthcare infrastructure with increasing prevalence of urothelial cancer. Asia Pacific shows the fastest growth in the market due to the low cost of R&D. India and China are expected to be the fastest growing market for bladder cancer treatment.

The Middle East and Africa has the lowest market for urothelial carcinoma treatment due to poor medical facilities and lack of technology.

Inquire for Discount at https://www.marketresearchfuture.com/check-discount/6444

About Market Research Future: MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar, Pune

+1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Urothelial Carcinoma Treatment Market Therapeutics Survey Report by GlaxoSmithKline plc, Genentech, Inc., Novartis AG, Dendreon, Merck KGaA, Eisai Co., Sanofi S.A., Bristol-Myers Squibb | MRFR Briefing 2018 here

News-ID: 1433349 • Views:

More Releases from Market Research Future

Denim Market Size By 2035 with 5.25 USD Billion in 2025 to 132.4 USD Billion, Due To Due to increasing popularity of Denim jeans, Denim jackets, and other denim apparel.
Denim Market Size By 2035 with 5.25 USD Billion in 2025 to 132.4 USD Billion, Du …
Denim Market Size Grow at a 75.25 USD Billion in 2025 to 132.4 USD Billion by 2035, CAGR of 5.81% By 2025 - 2035 Global Denim Market is entering a new phase of transformation as consumer demand, fashion cycles, and sustainable innovation continue to reshape the industry. Denim, once considered a classic wardrobe staple, has evolved into a versatile, fashion-driven category supported by innovations in fabric technology, eco-friendly production, and shifting
Humanoid Robots Market Size to Reach USD 13.8 Billion by 2032, Growing at 50.2% CAGR from 2024
Humanoid Robots Market Size to Reach USD 13.8 Billion by 2032, Growing at 50.2% …
The global Humanoid Robots Market is projected to reach USD 13.8 Billion by 2032, growing at a robust CAGR of 50.2% during the forecast period from 2024 to 2032. Driven by advancements in artificial intelligence, machine learning, and machine vision, humanoid robots-designed with human-like characteristics-are witnessing widespread adoption across healthcare, education, space exploration, and service industries. These robots are enhancing operational efficiency, performing complex tasks, and improving customer engagement across multiple
Vertical Farming Market Expansion: USD 9.023 Billion in 2025 Growing to USD 58.83 Billion by 2035
Vertical Farming Market Expansion: USD 9.023 Billion in 2025 Growing to USD 58.8 …
The Vertical Farming Market was estimated at USD 7.48 Billion in 2024 and is projected to grow from USD 9.023 Billion in 2025 to USD 58.83 Billion by 2035, exhibiting a robust CAGR of 20.62% during the forecast period from 2025 to 2035. Driven by increasing demand for sustainable agriculture, urbanization, and technological advancements in controlled-environment farming, vertical farming solutions are seeing widespread adoption across commercial, industrial, and urban agriculture sectors. Key
Robotics Market Trends and Forecast: USD 74,120.70 Million in 2024 Expected to Hit USD 476,019.67 Million by 2035
Robotics Market Trends and Forecast: USD 74,120.70 Million in 2024 Expected to H …
The Robotics Market was valued at USD 74,120.70 Million in 2024 and is projected to reach USD 476,019.67 Million by 2035, growing at a robust CAGR of 18.4% during the forecast period from 2024 to 2035. Driven by advancements in medical robots, growing industrial robotics adoption, and the development of AI technologies, robotics solutions are witnessing widespread adoption across healthcare, manufacturing, logistics, and service sectors. Despite challenges like high initial costs

All 5 Releases


More Releases for Urothelial

Rising Bladder Cancer Cases Fueling Growth In The Urothelial Carcinoma Treatment …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Urothelial Carcinoma Treatment Market Size Valuation Forecast: What Will the Market Be Worth by 2025? The market segment dedicated to treating urothelial carcinoma has experienced swift expansion lately, projected to increase its value from 2.86 billion USD in 2024 to 3.36 billion USD the following year, reflecting a compound
Emerging Trends Influencing The Growth Of The Metastatic Urothelial Carcinoma Ma …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries. How Big Is the Metastatic Urothelial Carcinoma Market Size Expected to Be by 2034? The market size for metastatic urothelial carcinoma has seen exponential growth recently. The market will expand from a worth of $1.18 billion in 2024 to $1.42 billion in 2025, with a compound annual growth rate (CAGR) of 20.2%.
Urothelial Cancer Drugs Market for Bladder and Urinary Tract Tumors | Driven by …
Urothelial Cancer Drugs market is expected to grow at a CAGR Of 21.2% during the forecast period 2024-2031. The Urothelial Cancer Drugs Market report by DataM Intelligence provides comprehensive insights and analysis on key market trends, growth opportunities, and emerging challenges. With a commitment to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. By combining qualitative and quantitative research methodologies, the firm
Major Market Shift in Urothelial Carcinoma Treatment Industry: Innovations In Ur …
What Is the Forecasted Market Size and Growth Rate for the Urothelial Carcinoma Treatment Market? In the recent years, there has been a swift escalation in the size of the urothelial carcinoma treatment market. It is projected to expand from $2.86 billion in 2024 to $3.37 billion in 2025, boasting a Compound Annual Growth Rate (CAGR) of 18.0%. The growth during the past period can be credited to an upsurge in
Urothelial Carcinoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Urothelial Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 40+ Urothelial Carcinoma companies and 50+ pipeline drugs in the Urothelial Carcinoma pipeline landscape. It covers the Urothelial Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Urothelial Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways
Urothelial Carcinoma Pipeline Insights Report 2024
DelveInsight's, "Urothelial Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 40+ Urothelial Carcinoma companies and 50+ pipeline drugs in the Urothelial Carcinoma pipeline landscape. It covers the Urothelial Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Urothelial Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways